HC Wainwright Reiterates Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC)

HC Wainwright reiterated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Thursday, Benzinga reports. HC Wainwright currently has a $54.00 target price on the stock. A number of other research firms have also issued reports on RNAC. Needham & Company LLC reaffirmed a buy rating and […]

Related Keywords

United States ,American ,Leerink Partnrs ,Hall Laurie ,Timothya Springer ,Securities Exchange Commission ,American International Group Inc ,Delphi Financial Group Inc ,Needham Company ,Cartesian Therapeutics Inc ,Sg Americas Securities ,Cartesian Therapeutics ,Free Report ,Therapeutics Stock Down ,Get Free Report ,Director Timothy ,Exchange Commission ,Lauriej Trustee ,International Group ,Financial Markets ,Delphi Financial Group ,Cartesian Therapeutics Daily ,